SCHEMBL4164464

SCHEMBL4164464

C#CCN1C(=O)C2(NC(=O)NC2=O)c2cc(F)ccc21

nearest known ligand 0.53

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 18/20 0.53
AKR1A1 P14550 14/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4174404 0.85 AKR1B1 (0.39) AKR1B1AKR1A1
SCHEMBL4166938 0.82 ITGA4 (0.49) AKR1B1AKR1A1
SCHEMBL4267235 0.81 AKR1B1 (0.50) AKR1B1AKR1A1
SCHEMBL4260419 0.80 PARK7 (0.51) AKR1B1AKR1A1
SCHEMBL4163269 0.80 AKR1B1 (0.49) AKR1B1AKR1A1
SCHEMBL3950566 0.79 AKR1B1 (0.42) AKR1B1AKR1A1
SCHEMBL4169609 0.79 AKR1B1 (0.48) AKR1B1AKR1A1
SCHEMBL4164837 0.79 AKR1B1 (0.48) AKR1B1AKR1A1
SCHEMBL4259309 0.79 AKR1B1 (0.48) AKR1B1AKR1A1
SCHEMBL4262927 0.79 AKR1B1 (0.48) AKR1B1AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 AKR1B1 344/4885AKR1A1 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.